Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirikizumab Bioequivalence Study in Healthy Participants
NCT07446101Phase 1Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2026
- Primary completion
- Feb 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised trial of mirikizumab in ulcerative colitis (UC) (3 arms), sponsored by Eli Lilly and Company. Primary endpoints: Maximum Concentration and Area Under the Concentration Versus Time Curve. Started Mar 2026; status: recruiting.
02
Drugs
mirikizumab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT07446101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07446101.